News | March 21, 2026
Pfizer warns shareholders against Tutanota’s mini-tender offer
Pfizer recommends that shareholders do not tender their shares in response to Tutanota’s offer
Pfizer recommends that shareholders do not tender their shares in response to Tutanota’s offer
The Flonase Allergy Relief Nasal Spray, 50 mcg per spray market achieved annual sales of approximately $384.7 million
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
Giri stated he is stepping down to pursue new opportunities after careful consideration
Emcure to distribute Roche's kidney transplant and anemia drugs in India
The product addresses a market with approximately $66.8 million in annual sales as of December 2025.
Vinita has made expansion in the U.S. a core pillar of Lupin’s worldwide growth strategy
The clinical program has benefited from extensive European Union support, including the IMI2 TRIC-TB and UNITE4TB projects, as well as funding from the EDCTP2 bEto-TB project
The FDA’s Center for Biologics Evaluation and Research (CBER) cited Moderna’s choice of a licensed standard-dose flu vaccine as the comparator in its Phase 3 trial, saying it “does not reflect the best-available standard of care.”
Subscribe To Our Newsletter & Stay Updated
